-
Information-Publications
-
Optimization of cationic polymer-mediated transfection for RNA interferenceDetails
-
Engineering an adenine base editor in human embryonic stem cells with minimal DNA and RNA off-target activitiesDetails
-
Engineering of near-PAMless adenine base editor with enhanced editing activity and reduced off-targetDetails
-
PE-STOP: A versatile tool for installing nonsense substitutions amenable for precise reversionDetails
-
Large-scale multiplexed mosaic CRISPR perturbation in the whole organismDetails
-
Amelioration of nitroglycerin-induced migraine in mice via Wuzhuyu decoction: Inhibition of the MZF1/PGK1 pathway and activation of NRF2 antioxidant responseDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands